EUSA Pharma announces 10-year outcome data of PROSTASCINT in prostate cancer radiotherapy

October 31, 2017

"Exon level arrays represent a significant step up in our ability to interrogate the genome in greater detail than traditional 3 prime biased arrays," said early access user Stuart Pepper, head of the Cancer Research U.K. Molecular Biology Core Facility at the Paterson Institute for Cancer Research, The University of Manchester. "Our initial work with these arrays has shown that we can obtain very clean data which will facilitate the detection and quantitation of alternate transcript expression."

Agilent offers catalog content for human, mouse and rat in 4x180K (four arrays per slide, 180,000 features each) and 2x400K formats, letting users choose between cost, throughput and comprehensive coverage. Like its other microarrays, Agilent also provides custom options for the human, mouse and rat SurePrint G3 Exon products. Custom formats include 8x60K, 4x180K, 2x400K and 1x1M.

Like all Agilent microarrays, the SurePrint G3 Exon solution delivers a wide dynamic range to detect low expressors and high expressors to accurately represent the range of expression levels and provide high confidence in the results.

SOURCE Agilent Technologies Inc.